Roche steps up Tamiflu distribution in US cities

16 January 2006

Swiss drug major Roche says that it has stepped up Tamiflu (oseltamivir) distribution in US cities where a high incidence of influenza is being reported, and will continue to meet seasonal demand for the prescription antiviral medication. Roche is shipping Tamiflu directly to wholesalers in those markets. States that have seen a particularly high increase in flu incidence recently include California, Arizona, New Mexico, Utah, Texas, Oregon, Nevada and Kansas, the firm notes.

Roche expained that it implemented a proactive inventory management plan last fall, following a huge spike in Tamiflu demand that was driven by fears of a potential avian flu pandemic. By temporarily halting some product shipments prior to the 2005/2006 flu season, the company maintained the ability to distribute Tamiflu to US markets with confirmed influenza cases, while preserving a pipeline to ensure continued availability. Local pharmacies can order additional product from their wholesalers based on increased demand, ensuring that Tamiflu is available to patients with a doctor's prescription.

"When demand for Tamiflu rose last year, Roche took appropriate precautions to ensure adequate supplies would be available for the treatment and prevention of seasonal influenza," said George Abercrombie, chief executive of Hoffmann-La Roche Inc. "Because of those precautionary measures, Tamiflu is readily and widely available to patients who need it for flu treatment and prevention, while we continue to work with governments to supply stockpiles for pandemic preparedness," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight